Ronald T. Borchardt Appointed to Ricerca, LLC Scientific Advisory Board

Apr 04, 2001, 01:00 ET from Ricerca, LLC

    CONCORD, Ohio, April 4 /PRNewswire/ -- Ricerca, LLC, a drug development
 company, has announced that Dr. Ronald T. Borchardt has joined its Scientific
 Advisory Board.  "Dr. Borchardt is an internationally recognized expert in
 pharmaceutical chemistry, in vitro drug absorption models and enzymatic
 chemistry," said Dr. Prabhavathi Fernandes, Ricerca CEO.  "His insights will
 help guide the establishment of our new discovery lead evaluation programs,
 which rely heavily on in vitro ADMET data to weed out compounds that are
 likely to fail, thus delivering optimized preclinical candidates."
     Dr. Borchardt is Summerfield distinguished professor of pharmaceutical
 chemistry at the University of Kansas, Lawrence, KS.  He is well known for his
 studies in the transport of drugs through the intestinal mucosa and the
 development of the Caco-2 in vitro model for transport of drugs.  He has
 served as an advisor for over thirty drug companies including Pharmacia,
 Hoffmann La Roche, Glaxo-SmithKline and Genentech, and currently serves on the
 Scientific Advisory Board of over ten biopharma companies.  He has over 400
 publications in leading and refereed scientific journals and two US patents.
 He currently sits on the editorial board of nine scientific journals and is
 the editor of several books.  He is an advisor to the National Institutes of
 Health, National Cancer Institute and American Heart Association.  His
 international awards include the Takeru and Aya Higuchi Memorial Award,
 Academy of Pharmaceutical Sciences and Technology, Japan, 1993; the Host-
 Madsen Medal, Federation Internationale Pharmaceutique, 1999; Distinguished
 Service Award-FASEB Research Conference on Biological Methylation, 1999;
 Millennial Pharmaceutical Scientist Award, Millennial World Congress 2000.  He
 currently is serving as president of the American Association of
 Pharmaceutical Scientists, 2001.
     Ricerca, LLC, a drug development company, offers technical expertise in
 late stage discovery through IND development.  The company speeds drug lead
 optimization and preclinical candidate selection through advanced Absorption,
 Distribution, Metabolism, Excretion and Toxicology (ADMET) technologies, and
 then helps its customers rapidly develop the preclinical Chemistry,
 Manufacturing and Controls (CMC) and nonclinical safety data to support filing
 of the Investigational New Drug application (IND).  When the drug enters human
 clinical investigations, Ricerca provides continued critical chemical process
 development and optimization, API production and clinical trial sample
 bioanalysis.  The company, privately owned by SG Capital Partners, LLC, New
 York, NY and Venture Biologics, LLC, Plymouth Meeting, PA is located near
 Cleveland, Ohio and has over 240 employees.
 
 

SOURCE Ricerca, LLC
    CONCORD, Ohio, April 4 /PRNewswire/ -- Ricerca, LLC, a drug development
 company, has announced that Dr. Ronald T. Borchardt has joined its Scientific
 Advisory Board.  "Dr. Borchardt is an internationally recognized expert in
 pharmaceutical chemistry, in vitro drug absorption models and enzymatic
 chemistry," said Dr. Prabhavathi Fernandes, Ricerca CEO.  "His insights will
 help guide the establishment of our new discovery lead evaluation programs,
 which rely heavily on in vitro ADMET data to weed out compounds that are
 likely to fail, thus delivering optimized preclinical candidates."
     Dr. Borchardt is Summerfield distinguished professor of pharmaceutical
 chemistry at the University of Kansas, Lawrence, KS.  He is well known for his
 studies in the transport of drugs through the intestinal mucosa and the
 development of the Caco-2 in vitro model for transport of drugs.  He has
 served as an advisor for over thirty drug companies including Pharmacia,
 Hoffmann La Roche, Glaxo-SmithKline and Genentech, and currently serves on the
 Scientific Advisory Board of over ten biopharma companies.  He has over 400
 publications in leading and refereed scientific journals and two US patents.
 He currently sits on the editorial board of nine scientific journals and is
 the editor of several books.  He is an advisor to the National Institutes of
 Health, National Cancer Institute and American Heart Association.  His
 international awards include the Takeru and Aya Higuchi Memorial Award,
 Academy of Pharmaceutical Sciences and Technology, Japan, 1993; the Host-
 Madsen Medal, Federation Internationale Pharmaceutique, 1999; Distinguished
 Service Award-FASEB Research Conference on Biological Methylation, 1999;
 Millennial Pharmaceutical Scientist Award, Millennial World Congress 2000.  He
 currently is serving as president of the American Association of
 Pharmaceutical Scientists, 2001.
     Ricerca, LLC, a drug development company, offers technical expertise in
 late stage discovery through IND development.  The company speeds drug lead
 optimization and preclinical candidate selection through advanced Absorption,
 Distribution, Metabolism, Excretion and Toxicology (ADMET) technologies, and
 then helps its customers rapidly develop the preclinical Chemistry,
 Manufacturing and Controls (CMC) and nonclinical safety data to support filing
 of the Investigational New Drug application (IND).  When the drug enters human
 clinical investigations, Ricerca provides continued critical chemical process
 development and optimization, API production and clinical trial sample
 bioanalysis.  The company, privately owned by SG Capital Partners, LLC, New
 York, NY and Venture Biologics, LLC, Plymouth Meeting, PA is located near
 Cleveland, Ohio and has over 240 employees.
 
 SOURCE  Ricerca, LLC